



Universiteit  
Leiden  
The Netherlands

## **Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation - a delicate balance**

Admiraal, R.

### **Citation**

Admiraal, R. (2017, March 15). *Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation - a delicate balance*. Retrieved from <https://hdl.handle.net/1887/46717>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/46717>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/46717> holds various files of this Leiden University dissertation.

**Author:** Admiraal, R.

**Title:** Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation - a delicate balance

**Issue Date:** 2017-03-15

**Individualized Dosing of Serotherapy in Allogeneic Hematopoietic Cell  
Transplantation**

-

**A Delicate Balance**

*Rick Admiraal*

The research described in this thesis was performed at the University Medical Center Utrecht, Utrecht, the Leiden University Medical Center, Leiden, and the Leiden Academic Center for Drug Research, Leiden University, Leiden, the Netherlands, and was supported by ZonMW (The Netherlands Organization for Health Research and Development, grant number 40-41500-98-11044).

Publication of this thesis was financially supported by Sanofi-Genzyme, Gamida Cell, Eurocept and Shire

Copyright © 2017 Rick Admiraal

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission from the author and publisher holding the copyright of the published articles.

Lay-out and printing: Optima Grafische Communicatie, Rotterdam, the Netherlands

Cover Design: Jacqueline van Gorp and Optima Grafische Communicatie

Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation

-  
A delicate balance

Proefschrift

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op woensdag 15 maart 2017  
klokke 16.15 uur

door

Rick Admiraal

geboren te Beverwijk  
in 1984

**Promotor:**

Prof. dr. C.A.J. Knibbe

**Co-promotoren:**

Dr. J.J. Boelens (Universitair Medisch Centrum Utrecht)

Dr. R.G.M. Bredius (Leids Universitair Medisch Centrum)

**Promotiecommissie:**

Prof. Dr. H. Irth (voorzitter)

Prof. Dr. M. Danhof (secretaris)

Prof. Dr. J.H.F. Falkenburg

Prof. Dr. T. van Gelder (Erasmus Universiteit Rotterdam)

Dr. C. van Kesteren (Universiteit Utrecht)

## CONTENTS

<b>Part I</b>	<b>Introduction</b>	<b>9</b>
Chapter 1	Individualized Dosing of Serotherapy in Allogeneic Hematopoietic Cell Transplantation: Scope and Intent of the Investigations	11
Chapter 2	Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling	33
<b>Part II</b>	<b>Pharmacokinetics of Serotherapy</b>	<b>49</b>
Chapter 3	Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing	51
Chapter 4	Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcomes	73
<b>Part III</b>	<b>Exposure-Response Relationships of Serotherapy</b>	<b>95</b>
Chapter 5	Association between Anti-Thymocyte Globulin Exposure and CD4+ Immune Reconstitution in Paediatric Haematopoietic Cell Transplantation: a Retrospective Pharmacodynamic Cohort Analysis	97
Chapter 6	Excellent T-cell Reconstitution and Survival Provided ATG exposure is Low or Absent after Pediatric Cord Blood Transplantation Blood 2016; 128:2734-2741	119
Chapter 7	Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances	137
Chapter 8	Impact of alemtuzumab exposure on clinical outcomes of hematopoietic cell transplantation: are we overdosing children using I.V. dosing close to transplantation?	171

<b>Part IV</b>	<b>Immune Reconstitution Predicting Clinical Outcome</b>	<b>181</b>
Chapter 9	Leukemia-free Survival in Myeloid Leukemia, but not in Lymphoid Leukemia, is Predicted by Early CD4+ Reconstitution following Unrelated Cord Blood Transplantation in Children: a Multicenter Retrospective Cohort Analysis	183
Chapter 10	Viral Reactivations and Associated Outcomes in Context of Immune Reconstitution after Paediatric Hematopoietic Cell Transplantation: a Retrospective Cohort Study of Consecutive Patients	191
<b>Part V</b>	<b>Clinical Implementation of Individualized Dosing in HCT</b>	<b>207</b>
Chapter 11	Individualized Conditioning Regimens in Cord Blood Transplantation: Towards Improved and Predictable Safety and Efficacy	209
<b>Part VI</b>	<b>Conclusions and Perspectives</b>	<b>237</b>
Chapter 12	Individualized Dosing of Serotherapy in Allogeneic Hematopoietic Cell Transplantation: Summary, Conclusions and Perspectives	239
Chapter 13	Nederlandse Samenvatting /Dutch Summary	259
<b>Chapter 14</b>	<b>Appendices</b>	<b>281</b>
	Curriculum Vitae	283
	List of Publications	285
	List of co-authors and affiliations	287
	List of Abbreviations	293
	Dankwoord/Acknowledgements	297



